| |
The need to establish insights from a large volume of data was a vital blueprint for an emerging biopharma company. Learn how a phased approach and common architecture in an integrated data platform laid the foundation for a long-term MDM solution. 
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Kevin Dunleavy While patent cliffs loom for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a July 11 research note from Morgan Stanley. |
|
|
|
By Annalee Armstrong Pfizer gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies. |
By Nick Paul Taylor Roche’s $2.7 billion bet on Carmot Therapeutics has delivered another early win. Participants in a phase 1 trial lost 7.3% of their body weight after taking Carmot’s oral GLP-1 prospect for four weeks, suggesting the candidate can hold its own against rival molecules from the likes of Eli Lilly and Pfizer. |
By Angus Liu CAR-T specialist Legend Biotech has reportedly received a takeover bid and has tapped Centerview Partners as a financial adviser to evaluate its options. The news led to a surge in the stock price of the company and its parent GenScript. |
By Darren Incorvaia In a first, three patients with autoimmune diseases have responded positively to allogeneic CAR-T therapy. The study, conducted in China and published in Cell on July 15, is the first sign of the potential of allogeneic CAR-T therapies in treating autoimmune diseases, according to William Blair analysts. |
By Zoey Becker With ten biosimilar options in play, AbbVie's star immunology drug lost 13% of its total market share since March, according to a new Samsung Bioepis report. |
By Conor Hale J&J MedTech put up $7.96 billion in revenue, below analysts’ expectations for the division, to equal a 2.2% reported gain compared to the second quarter of last year. |
By Helen Floersh New findings in mice suggest it’s possible to prevent organ damage from COVID-19 with an antioxidant enzyme that protects the mitochondria—without the risk of resistance. |
By Angus Liu A lengthy Form 483 details the concerns that led to the FDA's surprise rejection of Hengrui and Elevar's PD-1 inhibitor camrelizumab in May. Meanwhile, a separate Form 483 and a warning letter add to Hengrui's list of production problems. |
By Andrea Park In a survey of healthcare providers representing more than a dozen specialties by the physician influencer marketing agency MedFluencers, nearly 90% said they believe the pharma industry is underutilizing social media as a method of communication. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” Fierce Healthcare’s Anastassia Gliadkovskaya explores the topic of inequities in maternal and infant health and what one nonprofit is doing to increase transparency and accountability. |
|
|---|
|
|
|
Wednesday, August 7, 2024 | 11am ET / 8am PT Join us for this one-hour, deep dive to learn more about the rise of dynamic modular content as today's leading engagement strategy. Discover how this innovative digital design system is helping increase patient medication adherence and the length of therapies. 
|
|
Whitepaper Self-amplifying RNAs (also known as self-replicating RNAs), or saRNAs, are increasing in popularity as a platform for vaccine development. Download to learn how to make a more streamlined and efficient manufacturing of self-amplifying RNAs. Sponsored by: TriLink |
Whitepaper An insider’s workbook filled with practical tips and tools for designing and scaling a global patient support program. Sponsored by: Harte Hanks |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper When we talk about digital twins in the context of biology and medicine, we're inherently discussing a simplified model. These simplifications aren't a drawback but a necessity. Sponsored by: Unlearn |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper The Role of Environmental Monitoring in a Contamination Control Strategy Sponsored by: ThermoFisher Scientific |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
